Emily Wan, MD MPH

Panelists discuss how individualized chronic obstructive pulmonary disease (COPD) maintenance therapy considers symptom severity, exacerbation risk, and eosinophil levels. Dupilumab and ensifentrine require adherence to prescribed dosing for efficacy and safety.

Maintenance Therapy and Adherence to COPD Treatment

Video content above is prompted by the following:

What are key considerations when selecting individualized maintenance therapy for COPD?

What are the dosing and administration recommendations for dupilumab and ensifentrine? Is treatment adherence a concern with either agent?

Videos

Panelists discuss how the ENHANCE trials assessed ensifentrine in patients with chronic obstructive pulmonary disease (COPD) with moderate-to-severe airflow obstruction and a history of exacerbations. Outcomes showed improved lung function and reduced exacerbations. Clinically, ensifentrine may be used as monotherapy or an add-on, addressing diverse patient needs.

Ensifentrine (ENHANCE Trials) in COPD

Ensifentrine is recommended in the 2025 GOLD Report as a bronchodilator to improve dyspnea. Ensifentrine is also suggested as a potential anti-inflammatory therapy in stable COPD.

What were the main patient eligibility criteria and clinical outcomes in the ENHANCE trials?

How do you anticipate that ensifentrine will be used in clinical practice (ie, monotherapy, add-on, both)?

Panelists discuss how the BOREAS and NOTUS phase 3 trials demonstrated that dupilumab significantly reduced exacerbations, improved lung function, and enhanced quality of life in patients with uncontrolled chronic obstructive pulmonary disease (COPD), particularly those with elevated eosinophil counts, highlighting its potential in targeted therapy.

GOLD 2025 Report: Dupilumab, a New Treatment in COPD

The 2025 GOLD recommendations include the addition of dupilumab as the first biologic treatment to reduce the frequency of COPD exacerbations in stable COPD.

Discuss clinical outcomes with dupilumab in the BOREAS and NOTUS phase 3 trials.

Panelists discuss how ensifentrine is a nebulized inhaled therapy, a small molecule inhibitor of PDE3 and PDE4, and is compelling because there are very few adverse effects. There are also compelling results from studies that show bronchial dilatation and exacerbation reduction. 

GOLD 2025 Report: Ensifentrine, a New Treatment in COPD

The most impactful changes to the 2025 GOLD Report pertain to chronic obstructive pulmonary disease (COPD) management, specifically the addition of 2 new treatment options, ensifentrine and dupilumab, that were approved for use by the FDA in June 2024 and September 2024, respectively.

What is ensifentrine (first-in-class PDE3 and PDE4 inhibitor), and how do its effects translate for the management of stable COPD?

Emily Wan, MD MPH

Articles